Anda di sini
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 1651 | Vancomycin HCl 500mg Injection | J01XA01-110-P40-01-XXX | A* | i. Treatment of infections due to susceptible gram-positive organisms which cannot be treated with other agents (eg. MRSA and Enterococcus sp.) ii. Treatment of severe staphylococcal infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins. | None | Slow IV infusion. ADULT: 15-20mg/kg q 8-12 hours, not to exceed 2gm per dose. NEONATE up to 1 week, 15 mg/kg initially, then 10 mg/kg every 12 hours. INFANT 1 - 4 weeks, 15 mg/kg initially then 10 mg/kg every 8 hours. CHILD over 1 month, 10 mg/kg every 6 hours |
| 1652 | Varenicline Tartrate 0.5mg Tablet | N07BA03123T1001XX | A/KK | Smoking cessation treatment | 0.5 mg once daily for Day 1-3, then 0.5 mg twice daily for Day 4-7, then 1 mg twice daily; duration of treatment is 12 weeks | |
| 1653 | Varenicline Tartrate 1mg Tablet | N07BA03123T1002XX | A/KK | Smoking cessation treatment | 0.5 mg once daily for Day 1-3, then 0.5 mg twice daily for Day 4-7, then 1 mg twice daily; duration of treatment is 12 weeks | |
| 1654 | Varicella Virus Vaccine Live Attenuated Injection | J07BK01000P4001XX | A* | Immunisation against varicella virus infection. | 0.5ml by SC. Dosing is according to product insert. | |
| 1655 | Vasopressin 20 units/ml Injection | H01BA01000P3001XX | A | i) Pituitary diabetes insipidus ii) Oesophageal variceal bleeding | i) 5 - 20 units SC or IM every 4 hours ii) 20 units in 100 - 200 ml 5% dextrose saline over 15 minutes as infusion which may be repeated after at intervals of 1 - 2 hours. Maximum: 4 doses | |
| 1656 | Vedolizumab 300mg powder for concentrate for solution for infusion | L04AA33-000-P41-01-XXX | A* | i) Indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to tumour necrosis factor-alpha (TNF-α) antagonist. ii) Indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to tumour necrosis factor-alpha (TNFα) antagonist. | None | 300 mg administered by intravenous infusion at zero, two and six weeks and then every eight weeks thereafter. |
| 1657 | Venetoclax 100mg Film Coated Tablet | L01XX52-000-T32-01-XXX | A* | Indicated in combination with azacitidine, or decitabine, or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. | To be prescribed by Consultant Haematologist only. | The recommended dosage and ramp-up of venetoclax depends on the combination agent. Follow the dosing schedule, including the 3-day or 4-day dose ramp-up, as following: Day 1: 100mg, Day 2: 200mg, Day 3: 400mg, Day 4 and beyond: 400mg orally once daily of each 28-day cycle in combination with azacitidine or decitabine OR 600mg orally once daily of each 28-day cycle in combination with low-dose cytarabine. Continue venetoclax, in combination with azacitidine or decitabine or low-dose cytarabine until disease progression or unacceptable toxicity. |
| 1658 | Venetoclax 10mg Film Coated Tablet | L01XX52-000-T32-02-XXX | A* | Indicated in combination with azacitidine, or decitabine, or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. | To be prescribed by Consultant Haematologist only. | The recommended dosage and ramp-up of venetoclax depends on the combination agent. Follow the dosing schedule, including the 3-day or 4-day dose ramp-up, as following: Day 1: 100mg, Day 2: 200mg, Day 3: 400mg, Day 4 and beyond: 400mg orally once daily of each 28-day cycle in combination with azacitidine or decitabine OR 600mg orally once daily of each 28-day cycle in combination with low-dose cytarabine. Continue venetoclax, in combination with azacitidine or decitabine or low-dose cytarabine until disease progression or unacceptable toxicity. |
| 1659 | Venetoclax 50mg Film Coated Tablet | L01XX52-000-T32-03-XXX | A* | Indicated in combination with azacitidine, or decitabine, or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. | To be prescribed by Consultant Haematologist only. | The recommended dosage and ramp-up of venetoclax depends on the combination agent. Follow the dosing schedule, including the 3-day or 4-day dose ramp-up, as following: Day 1: 100mg, Day 2: 200mg, Day 3: 400mg, Day 4 and beyond: 400mg orally once daily of each 28-day cycle in combination with azacitidine or decitabine OR 600mg orally once daily of each 28-day cycle in combination with low-dose cytarabine. Continue venetoclax, in combination with azacitidine or decitabine or low-dose cytarabine until disease progression or unacceptable toxicity. |
| 1660 | Venlafaxine HCl 150 mg Extended Release Capsule | N06AX16110C2002XX | A* | i) Depression ii) Generalized anxiety disorder iii) Social anxiety disorder (social phobia) iv) Panic disorder | i), ii) & iii) ADULT: 75 mg once daily. May increase dose by 75 mg/day every 4 days to a maximum dose of 225 mg/day, (severe depression: max: 375mg/day) iv) 37.5 mg/day for the first 4-7 days after which the dose should be increased to 75 mg once daily. CHILD and ADOLESCENT under 18 years not recommended. | |
| 1661 | Venlafaxine HCl 75 mg Extended Release Capsule | N06AX16110C2001XX | A* | i) Depression ii) Generalized anxiety disorder iii) Social anxiety disorder (social phobia) iv) Panic disorder | i), ii) & iii) ADULT: 75 mg once daily. May increase dose by 75 mg/day every 4 days to a maximum dose of 225 mg/day, (severe depression: max: 375mg/day) iv) 37.5 mg/day for the first 4-7 days after which the dose should be increased to 75 mg once daily. CHILD and ADOLESCENT under 18 years not recommended | |
| 1662 | Verapamil HCl 2.5 mg/ml Injection | C08DA01110P3001XX | A/KK | Supraventricular tachycardia | Initially 5-10mg given by slow IV over at least 2 minutes. The dose can be repeated 10mg 30 minutes after the first dose if the initial response is not adequate. | |
| 1663 | Verapamil HCl 40 mg Tablet | C08DA01-110-T10-01-XXX | B | i) Supraventricular tachyarrhythmias (SVT) prophylaxis ii) Angina iii) Hypertension | i) 120-480mg in 2-3 divided doses ii) 80mg – 120mg 3 times daily iii) Initial: 240 mg daily in 2-3 divided doses. Max: 480 mg daily | |
| 1664 | Vildagliptin 50 mg and Metformin HCl 1000 mg Tablet | A10BD08926T1002XX | A/KK | FUKKM restriction: As add-on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. - Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. | 50 mg/850 mg or 50 mg/1000 mg twice daily. Maximum daily dose is 100 mg vildagliptin plus 2000 mg metformin hydrochloride. | |
| 1665 | Vildagliptin 50 mg and Metformin HCl 500 mg Tablet | A10BD08926T1003XX | A/KK | FUKKM restriction: As add-on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. - Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. | 50/500mg or 50/850mg or 50/1000mg twice daily. Maximum daily dose is 100mg vildagliptin and 2000mg metformin. | |
| 1666 | Vildagliptin 50 mg and Metformin HCl 850 mg Tablet | A10BD08926T1001XX | A/KK | FUKKM restriction: As add-on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. - Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. | 50 mg/850 mg or 50 mg/1000 mg twice daily. Maximum daily dose is 100 mg vildagliptin plus 2000 mg metformin hydrochloride. | |
| 1667 | Vildagliptin 50mg Tablet | A10BH02-000-T10-01-XXX | A/KK | Indicated as adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus, as monotherapy when metformin is contraindicated or not tolerated and as add-on therapy to other glucose-lowering agents when adequate glycaemic control is not achieved despite dose optimisation. | None | ADULT over 18 years: 50mg bd when combine with metformin, 50 mg od when combine with sulphonylurea |
| 1668 | Vinblastine Sulphate 10 mg Injection | L01CA01183P3002XX | A | Hodgkin's disease, choriocarcinoma resistant to other chemotherapeutic agents, non-small cell lung cancer, Langerhans cell histiocytosis | Adult: Initially, 3.7 mg/m2, increase dose weekly based on WBC counts in increments of about 1.8 mg/m2 until leukocyte count decreases to about 3000/mm3, or maximum weekly dose of 18.5 mg/m2 reached. Usual dose: 5.5-7.4 mg/m2 per week. Do not administer next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3. Child: Initial 2.5 mg/m2 of BSA, increased dose at weekly intervals in increments of about 1.25 mg/m2 until leukocyte count decreases to about 3000/ mm3, or maximum weekly dose of 12.5 mg/m2 reached. Do not increase dose once leukocyte count reaches approximately 3000 cells/mm3, instead, a dose of 1 increment smaller to be admin at wkly intervals for maintenance. Do not administer next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3. | |
| 1669 | Vincristine Sulphate 1 mg/ml Injection | L01CA02183P3001XX | A | i) Solid tumours ii) Gestational trophoblastic disease iii) Lymphoma iv) Multiple myeloma v) Acute lymphoblastic leukemia | ADULT 1.4 mg/m2 injection CHILD 1 mg/m2 to 2 mg/m2 weekly (0.05 mg/kg for infants less than 10kg) Dosing is according to product insert/protocol | |
| 1670 | Vinorelbine 10mg/mL Injection | L01CA04000P4002XX | A* | i) Advanced and metastatic non-small cell lung cancer ii) Advanced and metastatic breast cancer | As a single agent, the usual dose is 25 to 30 mg/m² administered weekly. In combination chemotherapy, the usual dose (25-30 mg/m²) is usually maintained, while the frequency of administration is reduced e.g. day 1 and 5 every 3 weeks or day 1 and 8 every 3 weeks according to treatment protocol. Dosing is individualised and according to product insert/protocol | |
| 1671 | Vitamin A 50,000 IU Capsule | A11CA01000C1001XX | C | Children with measles malnutrition and serious infections. Category C can use this drug for Orang Asli and in Sabah | i) 0-5 months, 50,000 IU ii) 6-11 months, 100,000 IU iii) 1-5 years, 200,000 IU. Frequency twice daily | |
| 1672 | Vitamin B Complex Tablet | A11EA00901T1001XX | C+ | Prophylaxis and treatment of vitamin B deficiency | 1-2 tablets daily | |
| 1673 | Vitamin B1, B6, B12 Tablet | A11DB00901T1001XX | B | For deficiency or raised requirement of Vitamin B1, B6, B12 | 1 tablets 3 times daily swallowed unchewed. | |
| 1674 | Vitamin K1 1 mg/ml Injection | B02BA01000P3001XX | C+ | Vitamin K deficiency in neonates | Prophylaxis of vitamin K deficiency bleeding in neonates Child: Neonate: 0.5-1 mg, given as a single dose via IM inj. Alternatively, 2 mg may be given orally, followed by a 2nd dose of 2 mg after 4-7 days. Intravenous Vitamin K deficiency bleeding in neonates Child: Infant: 1 mg by IV/IM/SC inj, further doses may be given if necessary. | |
| 1675 | Vitamin K1 10 mg/ml Injection | B02BA01000P3002XX | B | Haemorrhage associated with hypoprothrombinaemia caused by overdose of anticoagulants | 0.5 - 20 mg by very slow IV at a rate not exceeding 1 mg per minute | |
| 1676 | Voriconazole 200 mg Injection | J02AC03-000-P30-01-XXX | A* | i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, serious fungal infections caused by Scedosporium species and Fusarium species ii)Prevention of breakthrough fungal infections in febrile high-risk neutropenic patients | None | Adult and Children 12 years and greater: Loading dose: 6 mg/kg 12 hourly for first 24 hours. Maintenance: i) 4 mg/kg 12 hourly ii) 3 mg/kg 12 hourly. Dose may be increased to 4 mg/kg 12 hourly if response is inadequate. Children aged 2years to <12years with normal hepatic and renal function: No loading dose needed; 7mg/kg 12hourly |
| 1677 | Voriconazole 200 mg Tablet | J02AC03-000-T10-02-XXX | A* | i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, candidiasis of the oesophagus, serious fungal infections caused by Scedosporium species and Fusarium species ii) Prevention of breakthrough fungal infections in febrile high-risk neutropenic patients | None | Adult and Children 12 years and greater and over 40 kg: Loading dose: 400 mg 12 hourly for first 24 hours. Maintenance: 200 - 300 mg 12 hourly. Less than 40 kg: Loading dose: 200 mg 12 hourly for first 24 hours. Maintenance: 100 - 150 mg 12 hourly. Children aged 2years to <12years with normal hepatic and renal function: No loading dose needed; 200mg 12hourly |
| 1678 | Voriconazole 50 mg Tablet | J02AC03-000-T10-01-XXX | A* | i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, candidiasis of the oesophagus, serious fungal infections caused by Scedosporium species and Fusarium species ii) Prevention of breakthrough fungal infections in febrile high-risk neutropenic patients | None | ADULT and CHILDREN 12 years and greater and over 40 kg: Loading dose: 400 mg 12 hourly for first 24 hours. Maintenance: 200 - 300 mg 12 hourly. Less than 40 kg: Loading dose: 200 mg 12 hourly for first 24 hours. Maintenance: 100 - 150 mg 12 hourly |
| 1679 | Vortioxetine 10mg tablet | N06AX26-330-T32-01-XXX | A* | Treatment of major depressive episodes in adults. | Consultant/specialists for specific indications only, including Geriatricians and Neurologists | ADULT Initially 10 mg once daily, may be increased to max: 20 mg once daily or decreased to min: 5 mg once daily. ELDERLY Initially 5 mg once daily. |
| 1680 | Warfarin Sodium 1 mg Tablet | B01AA03520T1001XX | B | Treatment and prophylaxis of thromboembolic disorders | Initially 2 to 5mg per day. Maintenance dose 2-10mg daily according to the INR Dosing is individualised based on patient’s INR and according product insert/protocol/ guideline. |